Report of Foreign Issuer (6-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2018

Commission File Number

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☑ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note : Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note : Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☑

If “yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant)

Kate Hill

Company Secretary

Date 18 October 2018

LOGO

SEC RELEASE

18 October 2018

KAZIA RAISES A$3.4 MILLION TO PROGRESS R&D PROGRAMS

Sydney, Thursday, 18 October 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the completion of a placement of ASX shares, primarily to sector-specialist institutional investors in Australia and internationally, at a price of A$0.38 per share. The placement will raise approximately A$3.4 million (exclusive of costs).

Institutional Placement

Under the terms of the placement, approximately 8.9 million new ASX-listed fully-paid ordinary shares have been allocated to institutional, professional, and sophisticated investors outside the United States at a price of A$0.38 per share, representing an 11.6% discount to the last closing price on Friday 12 October 2018 (A$0.43). Settlement and issuance of shares is expected to occur in several tranches during the week beginning Monday 22 ^nd October 2018.

The proceeds from the placement and SPP will be used to fund the Company’s R&D activities and provide working capital into 2020, yielding four critical value-driving data read-outs across the GDC-0084 and Cantrixil programs.

No shareholder approval is required for the placement. The placement shares will be allocated using the Company’s available placement capacity under its 15% limit in accordance with ASX Listing Rule 7.1 and its additional 10% limit in accordance with ASX Listing Rule 7.1A. The placement shares will rank equally with the Company’s existing shares on issue.

[ENDS]

The securities referred to in this announcement have not been, nor will be, registered under the US Securities Act of 1933 ( Securities Act ), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, such securities may not be offered or sold, directly or indirectly, in the United States or to any US person (as defined in Rule 902 under the Securities Act) or to any person acting for the account or benefit of a US person, except in transactions (i) registered under the US Securities Act (which the Company has no obligation to do) or (ii) exempt from, or not subject to, the registration requirements of the Securities Act and any other applicable securities laws of any state or other jurisdiction of the United States.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director

Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director

Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024